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Summary Carotid intima—media thickness (cIMT) and carotid plaque are ultrasound imaging
measures of carotid atherosclerosis and strong predictors of future stroke, myocardial infarction
and vascular death. The use of ultrasound measures of cIMT and carotid plaque as a screening
tool in clinical practice however have been extremely limited by a lack of recognition of its
value by medical communities, health care policy makers and a lack of reimbursement by third-
party payers engaged in the delivery of vascular imaging services. This review addresses the
role of cIMT and plaque in vascular disease risk prediction. Recent data from large population
based studies on reclassiﬁcation of the vascular risk using carotid ultrasound imaging markers
is presented. In addition, the common clinical scenarios for the appropriate use of cIMT in
clinical setting are summarized according to the recent study conducted by the Society of the
Atherosclerosis Imaging and Prevention in collaboration with the International Atherosclerosis
Society. This presentation is intended to provide a practical guide for use of cIMT and plaque to
clinicians to promote optimal clinical use of cIMT and to researchers to direct cIMT and plaque
research towards investigating environmental and genetic factors of a complex disorder — sub-
clinical atherosclerosis — leading to future genetic discoveries and new anti-atherosclerotic
d
o
 accestherapies.
© 2012 Elsevier GmbH.
Introduction
OpenAtherosclerosis is a complex inﬂammatory process under-
lying the occurrence of heart attacks and most ischemic
strokes. Traditional vascular risk factors are important for
∗ Corresponding author. Tel.: +1 305 243 7847;
fax: +1 305 243 7081.
E-mail address: trundek@med.miami.edu (T. Rundek).
1 Current address: Department of Psychiatry and Psychotherapy,
Albert-Ludwigs-University Freiburg, Freiburg, Germany.
a
r
l
p
c
c
p
a
o
i
2211-968X© 2012 Elsevier GmbH.
doi:10.1016/j.permed.2012.01.006
Open access under CC BY-NC-ND license.evelopment of atherosclerosis but interestingly, explain
nly about 50% of the risk of cardiovascular disease (CVD)
nd stroke. Current screening strategies are based on these
isk factors. However the complexity of stroke and CVD has
ed to the increasing use of intermediate phenotypes in risk
rediction of vascular disease and surrogate outcomes in
linical trials. Carotid intima—media thickness (cIMT) and
arotid plaque are widely used as intermediate, preclinical
s under CC BY-NC-ND license.henotypes of vascular disease (Fig. 1). Although individu-
ls with subclinical atherosclerosis have not yet experienced
vert vascular disease, they have a greater risk for
ncident stroke and MI in comparison to individuals without
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vidence of increased subclinical atherosclerotic disease.
arotid ultrasound imaging measures of carotid plaque and
IMT are proposed as surrogate markers of CVD and stroke
s objective indicators of the biological and pathobiolog-
cal processes of atherosclerosis. They can also serve as
urrogate endpoints for clinical vascular outcomes based on
pidemiologic, therapeutic, pathophysiologic and other sci-
ntiﬁc evidence. This review article will provide an overview
n the relevant literature regarding the use of cIMT and
arotid plaque as surrogate markers in various research
nvestigations and clinical practice.
hat is carotid intima—media thickness
cIMT)?arotid IMT is a widely accepted imaging surrogate marker
f generalized atherosclerosis [1,2]. On ultrasound, cIMT is
epresented by a double-line pattern on the near and the
ar wall of the carotid artery (Fig. 2). The two anatomical
igure 2 Assessment of carotid IMT.
easurement of the IMT in the far wall of the common carotid
rtery (CCA) with an IMT mean of 0.625± 0.045mm. IMT was
easured by an automatic edge detection algorithm as repre-
ented by the yellow and purple lines (the green line in the
umen of the CCA represents the reference value for the arterial
all echo gradient calculations).
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andmarks which can bemeasured as the double-line pattern
re the lumen—intima and the media—adventitia interfaces
3]. Even without presence of atherosclerosis the intima and
he media layer increase with advancing age as a result of
daptive changes to biomechanical parameters, like blood
ow and tension on the wall [4]. Since these changes give
ise to molecular and cellular pathways, which are also
nvolved in the formation of atherosclerotic plaque, cIMT is
elated to subclinical atherosclerosis, but should not be used
ynonymously [5]. According to large studies, such as The
therosclerosis Risk in Communities (ARIC) study, The Car-
iovascular Health Study (CHS), and The Rotterdam study,
correlation between cIMT measurements and risk of car-
iovascular events has been established [1,4,6]. Inversely,
connection between the reduction of intima—media pro-
ression with lipid-lowering therapies and a reduction of
ardiovascular risk shown in clinical trials [7,8] has lead
o considering cIMT a surrogate end point for the effect of
nti-atherosclerotic therapy [9]. This is an important fact
or risk evaluation since cIMT appears at an early stage of
therosclerosis when alterations in treatment can substan-
ially change the course of the disease more effectively. The
dvantage of measuring the cIMT by high resolution B-mode
ltrasonography lies in its rapidly applicable and available,
on-invasive and cost-effective nature [3]. Progression of
IMT is therefore an attractive method for use in research
s it can be easily assessed to study vascular risk or the
herapeutic effects of a speciﬁc treatment. Nevertheless,
vidence considering cIMT as a surrogate marker for CVD is
till a matter of debate [2,10—12].
hat is atherosclerosis?
n order to understand the distinctive nature of cIMT and
arotid plaque in the risk of stroke and CVD the process of
therosclerosis has to be clearly understood. About 10—20%
f ischemic strokes are due to large artery atherosclerosis,
ainly located in the extracranial arteries [13]. Atheroscle-
otic process leads to luminal stenosis, ﬂow restriction
nd plaque rupture and is therefore a strong predictor of
schemic stroke [14]. Atherosclerosis is a chronic inﬂam-
atory process, involving endothelial injury, activation and
ecruitment of immune-inﬂammatory cells, smooth muscle
ell proliferation, and inﬂux of lipoprotein [15]. Various
ediators like chemokines, cytokines, growth factors,
roteases, adhesion molecules, hemostasis regulators, and
heir interactions are involved in the process of plaque
rowth. Proinﬂammatory signaling is triggered by oxidized
ow-density lipoprotein (LDL) or through alterations and
emodeling in the extracellular matrix [9,16]. This process
eads to different plaque composition with variable vascular
isk due to different susceptibility for plaque rupture result-
ng in artery-to-artery embolization. Depending on the stage
f the atherosclerotic changes in the vessel wall there is a
ariety in plaque morphology. It differs from homogeneous
hickening of the wall to hyperechogenic components
onsisting mainly of ﬁbrous tissue and calciﬁcation, and
ypoechogenic components representing areas with athero-
atous material like lipid deposits, cell debris and necrotic
aterial. Hypoechogenic components are considered more
armful due to their instability [17]. Atherosclerosis pre-
ominantly develops at speciﬁc sites in the vessel, mainly
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areas with altered blood ﬂow, like bifurcations, branch
points and areas of vessel curvature. The mass transport and
the shear stress theory are two hypotheses about ﬂow reg-
ulated mechanical forces contributing to atherosclerosis. In
case of the ﬁrst theory a low or disturbed blood ﬂow results
in an increased uptake of bioactive substances into the
vessel wall, whereas in the latter theory mechanical forces
of blood ﬂow on the vessel wall, called shear stress, play an
important role in protection of endothelial function [16].
Surrogate markers of atherosclerosis
According to the NIH Deﬁnition Working Group, surrogate
markers act as a substitute for a clinical end point and
should be able to predict the desired clinical beneﬁt, respec-
tively the lack of beneﬁt, or harm, based on epidemiologic,
therapeutic, pathophysiologic or other scientiﬁc evidence
[18]. Biological markers are objectively measured and eval-
uated as an indicator of normal biological or pathogenic
processes, or pharmacologic response to a therapeutic inter-
vention. The clinical end point is deﬁned as a variable that
reﬂects how the patient feels, functions, or survives. Alter-
ation of these markers should be displayed in a change of a
clinically relevant end point [9]. The interest to use sur-
rogate markers in order to assess the effectiveness of a
treatment is increasing rapidly. Traditional biomarkers like
blood pressure and serum cholesterol are used widely for risk
assessment and in the development of treatment. Despite
effective treatments of traditional risk factors, a large num-
ber of individuals experience CVD, which shows the need
for investigations of other surrogate markers to help in the
search for novel therapies [9].
There are numerous risk factors, which are currently
used for the screening of atherosclerosis. Besides traditional
vascular risk factors like high blood pressure, diabetes,
smoking, stress, obesity, and metabolic syndrome, there
is a growing list of less traditional and soluble markers
such as high LDL or low HDL, CRP, LP (a), homocysteine,
LDL particle size, Lp-PLA2, ApoB/ApoA [19]. Additionally,
screening for atherosclerosis can be accomplished by imag-
ing methods for arterial structure or function. Among the
imaging methods for arterial structure, ultrasound measures
of cIMT and plaque are most widely used. Furthermore,
aortic and carotid plaque can be assessed by MRI, and the
coronary calcium score by electron beam CT (EBCT) [20,21].
Brachial vasoreactivity measured by ultrasound, vascular
compliance measured by radial tonometry and microvascu-
lar reactivity measured by ﬁngertip tonometry are examples
of arterial function tests that have been rapidly devel-
oping for the assessment of subclinical atherosclerosis
[22,23].
Blood pressure and LDL-cholesterol are FDA-approved
surrogate markers of cardiovascular disease while ultra-
sound measure of cIMT is still awaiting its ﬁnal approval and
validation by the FDA [3,9].
Carotid IMT in epidemiological studies and
clinical trials
Carotid IMT has been associated with increased risk of car-
diovascular events in large epidemiological studies. In a
t
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ystematic review and meta-analysis, eight observational
opulation-based studies were examined and showed the
igniﬁcant association of cIMT with risk of CVD [2]. Based
n the data from general population, cIMT showed a
lightly higher risk for stroke (hazard ratio, HR 1.32; 95%
I, 1.27—1.38) than for myocardial infarction (HR 1.26;
5% CI, 1.21—1.30). However, there are limitations to the
nterpretation of these results, especially concerning vari-
ble methodology, e.g. difference in deﬁnitions of carotid
egments or the way the measurements were reported.
herefore the importance of following standardized cIMT
rotocols is emphasized for future studies.
In the clinical trials, a systematic review and meta-
nalysis of the effect of LDL-lowering by statins on the
hange of cIMT was examined [24]. Analysis of nine
ipid-lowering trials showed a strong correlation between
eduction of LDL and cIMT, with each 10% reduction in LDL-
holesterol accounting for a reduction of cIMT by 0.73% per
ear.
Although the association of cIMT and increased risk of
ardiovascular events has been established, there is still
lack of sufﬁcient evidence to show whether lowering of
IMT will translate in the reduction in CVD. Furthermore,
ubclinical atherosclerosis is to some extend considered a
on-causal and nonspeciﬁc marker of atherosclerotic com-
lications [2,25]. Diverse approaches for measuring cIMT
nd a lack of uniﬁed criteria for distinguishing early plaque
ormation from thickening of the cIMT might contribute to
he fact of missing evidence on risk prediction. The imple-
entation of standardized methods in the measurement
f cIMT is necessary for further investigations since cIMT
epicts early atherosclerosis as well as nonatherosclerotic
ompensatory enlargement, with both phenotypes having a
ifferent impact on predicting vascular events [3,25].
oes carotid IMT add to prediction of CVD
eyond traditional risk factors?
urrent studies on the effect of cardiovascular risk factors
n conjunction with measures of atherosclerosis (cIMT and
laque) on risk prediction indicate a small but incremen-
al effect for risk prediction of CVD. In the recent analysis
rom the community-based ARIC study among 13,145 sub-
ects, approximately 23% individuals were reclassiﬁed into
different risk category group after adding information on
IMT and carotid plaque [11]. Adding cIMT to traditional
isk factors provided the most improvement in the area
nder the receiver-operating characteristic curve (AUC),
hich increased from 0.74 to 0.765. Adding plaque to the
IMT and traditional risk factors had however the best
et reclassiﬁcation index of 10% in the overall population.
n the Cardiovascular Health Study, another population-
ased study among 5888 participants, the elevated CRP was
ssociated with increased risk for CVD only among those
ndividuals who had increased cIMT and plaque detectable
n carotid ultrasound. Despite these signiﬁcant associations
ith CVD, CRP, cIMT and plaque only modestly improved
he prediction of CVD outcomes after accounting for the
raditional risk factors [26]. Addition of CRP or subclinical
arotid atherosclerosis to conventional risk factors resulted
n a modest increase in the ability to predict CVD. In the
1 S. Bartels et al.
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OMAS population, presence of carotid plaque considerably
ontributed to the better estimation of 10-year Framingham
ascular risk [14]. More than a half of individuals in low and
oderate FRS categories were reclassiﬁed into the higher
isk category if carotid plaque was present. Traditional CVD
isk prediction schemes need further improvement and cIMT
nd plaque may help improve CVD risk prediction with a
irect implication for the risk stratiﬁcation and treatment
n vascular preventive programs.
arotid IMT in different carotid artery sites
he localization of atherosclerosis is determined by hemo-
ynamic forces, like shear stress and tensive forces, and
dditional local predisposing factors [27]. Since these local
actors and hemodynamical forces are distributed variably
n the carotid vessels there are differences in the distri-
ution and development of cIMT. A population-based study
n the association of IMT at various sites and cardiovas-
ular risk factors showed that IMT in the common carotid
rtery (CCA IMT) is correlated with risk factors for stroke
nd prevalent stroke. Conversely, intima—media thickness
n the bifurcation, together with carotid plaque, were more
irectly associated with risk factors of ischemic heart dis-
ase and prevalent ischemic heart disease [28]. Systolic
lood pressure seems to be the most important factor inﬂu-
ncing IMT in the common carotid artery, whereas smoking
ay be more important for IMT in the internal carotid artery
ICA IMT). Both sites of IMT were independently associated
ith prevalent CVD, with the ICA IMT having a larger area
nder the ROC (receiver operating characteristic) curve than
CA IMT (0.756 vs. 0.695) [29]. Furthermore, evidence from
population-based study showed variation in the progres-
ion of IMT at different arterial sites [30]. Progression rate
f ICA IMT was signiﬁcantly greater compared to IMT in the
ifurcation or in the common carotid artery. In addition,
CA IMT correlated better with vascular risk factors than
CA IMT. The results suggest that ICA IMT might be a bet-
er measure of CVD than the more frequently investigated
CA IMT.
arotid atherosclerotic plaque vs. cIMT
arotid plaque is a distinctive phenotype of atherosclerosis
14]. Carotid IMT, however, is mainly related to hyperten-
ion resulting in a hypertrophy of the media layer of the
essel wall [31]. There is evidence of genetic inﬂuence
n cIMT, whereas carotid plaque is strongly inﬂuenced by
nvironmental factors [14,32]. Although cIMT has been asso-
iated with increased risk of cardiovascular disease, carotid
laque is a stronger predictor of cardiovascular disease in
arge population-based studies [33]. Nevertheless, differen-
iation of early plaque formation from increased cIMT is hard
o determine. Although cIMT and plaque share the effect
f atherosclerotic risk factors, they have different natural
istory, patterns of risk factors, and the prediction of vascu-
ar events. Since deﬁnition of carotid plaque varies, various
rofessional organizations have proposed a standard plaque
eﬁnition. According to the Mannheim consensus, plaque is
eﬁned as a focal structure encroaching into the arterial
umen of at least 0.5mm or 50% of the surrounding IMT value,
S
i
T
bFigure 3 Calciﬁed carotid plaque.
r demonstrates a thickness >1.5mm as measured from the
edia—adventitia interface to the intima—lumen interface
3].
Besides presence and plaque size, plaque composition or
orphology may be a better predictor or marker of vascu-
ar events [34]. Atherosclerosis, including plaque formation,
epresents a dynamic process involving a complex cascade
f inﬂammatory events from lipid deposition to plaque
alciﬁcation [35]. There is conﬂicting evidence about the
ffect of calciﬁed carotid plaque on cardiovascular events
34,36—38]. Echolucent, fatty plaques are considered more
armful, since they are less stable and therefore more prone
o rupture [39]. Individuals with calciﬁed or echodense
laque on the other hand, are less likely to have symp-
omatic disease [40]. In contrast, a signiﬁcant association
etween presence of carotid plaque calciﬁcation (Fig. 3.)
nd increased risk of vascular events was reported in a large
opulation based study [41].
Calciﬁed plaque appeared to be a signiﬁcant predictor
f combined vascular outcomes with a HR of 2.4 [95% CI,
.0—5.8] when compared to absence of plaque and after
djusting for demographics, mean cIMT, education and risk
actors. Another study evaluated the risk of cardiovascular
vents in the presence of plaque surface irregularities. Irreg-
lar plaque surface increased the risk of ischemic stroke by
-fold. The cumulative 5-year risk for ischemic stroke was
ver 8% for those with irregular plaque surface compared to
hose with regular plaque (<3%) [13]. Superﬁcial calciﬁcation
as been shown to play a role in instability of atherosclerotic
laque [42]. Whether soft, calciﬁed and irregular plaques
re different stages of the same process or separate entities
s a matter of controversy and longitudinal studies with care-
ul assessments of plaque progression are needed to resolve
hese issues.
arotid plaque and risk of CVD in
pidemiological studiesmall, non-stenotic carotid plaque is associated with an
ncreased risk of stroke and other vascular events [14].
he predictive power of presence of carotid plaque has
een demonstrated in several large observational studies
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[13,37,43—45]. In the Atherosclerosis Risk in Communities
study, a large population based study on 13,123 partici-
pants with a mean follow up of 8 years, the presence of
carotid plaque was associated with a 2-fold increased risk
of ischemic stroke [37]. Carotid plaque was associated with
a 1.7-fold increased risk of incident stroke in the Cardio-
vascular Health Study [46] over a mean follow-up time of
3.3 years and with a 1.5-fold increased risk in the Rotter-
dam Study [45] over a mean follow-up time of 5.2 years. In
the Northern Manhattan Study (NOMAS), presence of plaque
was associated with a 2.8-fold [HR 2.76, 95% CI, 2.1—3.63]
increased risk of stroke, MI and vascular death during a mean
follow up of 6.9 years [14]. Comparison between these stud-
ies however is limited due to diverse study populations and
different measuring methods of atherosclerotic plaque [14].
Carotid plaque area may be a better measure of
atherosclerosis than cIMT or plaque thickness, since evi-
dence suggests that plaque area grows at a double rate in
average than it thickens [47]. In the Tromso study, another
large population based study, total plaque area was a
stronger predictor for the incident ischemic stroke than
cIMT [31]. In 3240 men and 3444 women ultrasonographic
assessment of plaque area resulted in a HR of 1.23 (95% CI,
1.09—1.38) in men and 1.19 (95% CI, 1.01—1.41) in women
for 1 SD increase in square-root-transformed plaque area
when adjusted for other cardiovascular risk factors. The
multivariable-adjusted HR in the highest quartile of plaque
area versus no plaque was 1.73 (95% CI, 1.19—2.52) in men
and 1.62 (95% CI, 1.04—2.53) in women. The multivariable-
adjusted HR for 1 SD increase in IMT was 1.08 (95% CI,
0.95—1.22) in men and 1.24 (95% CI, 1.05—1.48) in women
[31].
Why carotid IMT and plaque are not commonly
accepted surrogate endpoints?
A recent large meta-analysis of 18 case—control and cohort
studies evaluated the value of cIMT and plaque in the
screening for coronary heart disease [10]. It included 2920
individuals with CHD and 41,941 without CHD and showed no
beneﬁt of these parameters as a screening tool, since the
discrimination between affected and unaffected individuals
was insufﬁcient. Similarly, another recent meta-analysis of
41 randomized trials showed that regression or slowed pro-
gression of cIMT with cardiovascular drugs did not affect the
risk of cardiovascular events [12].
This evidence indicated that cIMT may not completely
meet all criteria of a surrogate marker. A marker should
be sensitive, available, non-invasive, and easy to evaluate;
all of which are characteristics of cIMT and carotid plaque.
However, a causal relationship with the clinical outcome
would need to be established and these evidences are likely
to come from large longitudinal studies in low risk individuals
as well as from basic science research. Furthermore, to act
as a surrogate marker cIMT should be able to reﬂect the
full therapeutic effect on the clinical outcome which has
not been show yet [48]. Some new information will come
from an ongoing large multinational meta-regression study
investigating individual progression rate of cIMT and risk of
vascular outcomes [49].
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ho should be screened for carotid IMT and
laque? Current guidelines/appropriate and
ot appropriate indications
ith increasing incidence of CVD and stroke in the pop-
lation it is important to identify high-risk patients with
ubclinical manifestation of disease which will beneﬁt from
arly and aggressive therapy. The Mannheim cIMT consen-
us states that there is no need to ‘treat IMT values’ nor
o monitor IMT values in individual patients apart from
ew exceptions [3,50]. The current guideline for the use of
arotid IMT in assessment of cardiovascular risk in asymp-
omatic adults from 2010 gives carotid IMT class IIa rank
ith a level B for evidence for asymptomatic adults at
ntermediate risk. They emphasize the importance of fol-
owing clear recommendations on the use of appropriate
canning and reading imaging ultrasound methodology [51].
ccordingly, the American Society of Echocardiography rec-
mmends in their consensus statement, the use of carotid
MT assessment should be reserved for individuals with inter-
ediate cardiovascular risk with; e.g. at a 6—20% 10-year
isk of cardiovascular disease according to the Framing-
am Risk Score (FRS). Since some high-risk groups might
ot be addressed by this approach, there are further clin-
cal circumstances that should be considered: (1) family
istory of premature CVD in ﬁrst-degree relative (men <55
ears old, women <65 years old); (2) individuals younger
han 60 years old with severe abnormalities in a single risk
actor (e.g., genetic dyslipidemia) who otherwise would
ot be candidates for pharmacotherapy; or (3) women
ounger than 60 years old with at least two CVD risk
actors [5].
Appropriate use of measuring carotid IMT in the clini-
al setting was examined and summarized by the Society
f Atherosclerosis Imaging and Prevention and the Interna-
ional Atherosclerosis Society [52]. To prevent either under-
r over-utilization of IMT-measurements, common clinical
cenarios, including risk assessment in the absence of known
oronary heart disease (CHD), risk assessment in patients
ith known CHD, and serial carotid IMT imaging for mon-
toring of CHD risk status, were rated. The conclusion of
hese professional organizations was that appropriate indi-
ations for the use of cIMT is for individuals without CHD
ith intermediate risk, older, and individuals with metabolic
yndrome. The testing of low-risk or very high-risk CHD
ndividuals as well as serial cIMT testing is considered inap-
ropriate use of this method.
eginning of genetic discoveries
ommon vascular risk factors like hypertension, diabetes,
ypercholesterolemia, and nicotine play an important role
n the development of atherosclerosis. Therefore, the
reatment and control of these factors is a major tar-
et in prevention of stroke. However, these environmental
isk factors contribute only to about half of all cases of
therosclerotic disease [53]. Finding novel risk factors of
therosclerosis is of great importance for prevention of car-
iovascular disease [17]. The focus of preventing strategies
ends to shift towards the investigation of genetic factors.
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[44
ariation in cardiovascular risk in the population is likely
o be connected to variability in genes that are involved
n the endothelial inﬂammatory response to oxidized lipids
17]. Identifying factors underlying the variation of subclin-
cal atherosclerosis unexplained by traditional vascular risk
actors either deleterious or protective may help targeting
reventive strategies. As opposed to traditional thinking, we
ave found that the traditional vascular risk factors explain
nly 21% of the variance in the total carotid plaque burden
n a multi-ethnic population of NOMAS. The most explana-
ory risk factors include age, sex, pack-years of smoking,
ystolic blood pressure, diastolic blood pressure, antihy-
ertensive and lipid-lowering medications, and diabetes
ellitus status. An inclusion of less traditional risk factors
uch as LDL:HDL ratio, homocysteine levels, high school
ompletion, white blood cell count and LDL cholesterol to
he traditional model contributed only about additional 2%,
xplaining 23% of the variance in total carotid plaque bur-
en at best. Therefore variation in subclinical carotid plaque
urden is largely unexplained by known vascular risk fac-
ors. These results suggest that other unaccounted factors,
oth environment and genetic, play an important role in
he determination of subclinical atherosclerosis. Identiﬁca-
ion of these genetic and environmental factors underlying
nexplained subclinical atherosclerosis is of great impor-
ance for successful prevention of stroke and cardiovascular
isease, and is in the major focus for future investigations
eading to genetic discoveries and new anti-atherosclerotic
reatments.
onclusion
arotid IMT and carotid plaque are signiﬁcant predic-
ors of vascular events and 2D ultrasound measurement
f cIMT and carotid plaque is an inexpensive way to
etect individuals with increased atherosclerotic burden
nd risk of CVD, evaluate the effects of current and
ovel therapies and investigate new contributing fac-
ors. Many unaccounted factors, both environmental and
enetic, may play an important role in the determination
f atherosclerosis, underscoring the importance of further
IMT and carotid plaque research investigations for suc-
essful prevention and treatment of cardiovascular disease
nd stroke.
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